Literature DB >> 33156925

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.

Jay Y Spiegel1, Saurabh Dahiya2, Michael D Jain3, John Tamaresis1, Loretta J Nastoupil4, Miriam T Jacobs5, Armin Ghobadi5, Yi Lin6, Matthew Lunning7, Lazaros Lekakis8, Patrick Reagan9, Olalekan Oluwole10, Joseph McGuirk11, Abhinav Deol12, Andre Goy13, Khoan Vu14, Charalambos Andreadis14, Javier Munoz15, N Nora Bennani6, Julie M Vose7, Kathleen A Dorritie16, Sattva S Neelapu4, Frederick L Locke3, Aaron P Rapoport2, Brian T Hill17, David B Miklos1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33156925      PMCID: PMC8555382          DOI: 10.1182/blood.2020006245

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

1.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Authors:  Frederick L Locke; Armin Ghobadi; Caron A Jacobson; David B Miklos; Lazaros J Lekakis; Olalekan O Oluwole; Yi Lin; Ira Braunschweig; Brian T Hill; John M Timmerman; Abhinav Deol; Patrick M Reagan; Patrick Stiff; Ian W Flinn; Umar Farooq; Andre Goy; Peter A McSweeney; Javier Munoz; Tanya Siddiqi; Julio C Chavez; Alex F Herrera; Nancy L Bartlett; Jeffrey S Wiezorek; Lynn Navale; Allen Xue; Yizhou Jiang; Adrian Bot; John M Rossi; Jenny J Kim; William Y Go; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2018-12-02       Impact factor: 41.316

2.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

Review 3.  Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.

Authors:  Michael Byrne; Olalekan O Oluwole; Bipin Savani; Navneet S Majhail; Brian T Hill; Fredrick L Locke
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-04       Impact factor: 5.742

4.  Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Authors:  Victor A Chow; Ajay K Gopal; David G Maloney; Cameron J Turtle; Stephen D Smith; Chaitra S Ujjani; Mazyar Shadman; Ryan D Cassaday; Brian G Till; Yolanda D Tseng; Edus H Warren; Andrei R Shustov; Manoj P Menon; Sandra Bhark; Utkarsh H Acharya; Erin Mullane; Lindsay M Hannan; Jenna M Voutsinas; Ted A Gooley; Ryan C Lynch
Journal:  Am J Hematol       Date:  2019-05-21       Impact factor: 10.047

5.  Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

Authors:  Loretta J Nastoupil; Michael D Jain; Lei Feng; Jay Y Spiegel; Armin Ghobadi; Yi Lin; Saurabh Dahiya; Matthew Lunning; Lazaros Lekakis; Patrick Reagan; Olalekan Oluwole; Joseph McGuirk; Abhinav Deol; Alison R Sehgal; Andre Goy; Brian T Hill; Khoan Vu; Charalambos Andreadis; Javier Munoz; Jason Westin; Julio C Chavez; Amanda Cashen; N Nora Bennani; Aaron P Rapoport; Julie M Vose; David B Miklos; Sattva S Neelapu; Frederick L Locke
Journal:  J Clin Oncol       Date:  2020-05-13       Impact factor: 50.717

6.  Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma.

Authors:  Jennifer M Logue; Elisa Zucchetti; Christina A Bachmeier; Gabriel S Krivenko; Victoria Larson; Daniel Ninh; Giovanni Grillo; Biwei Cao; Jongphil Kim; Julio C Chavez; Aliyah Baluch; Farhad Khimani; Aleksandr Lazaryan; Taiga Nishihori; Hien D Liu; Javier Pinilla-Ibarz; Bijal D Shah; Rawan Faramand; Anna E Coghill; Marco L Davila; Bhagirathbhai R Dholaria; Michael D Jain; Frederick L Locke
Journal:  Haematologica       Date:  2021-04-01       Impact factor: 9.941

  6 in total
  17 in total

1.  Treating CAR-T relapses: check not checkmate.

Authors:  Jay Y Spiegel; Krishna V Komanduri
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

Review 2.  Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Authors:  Miguel-Angel Perales; Larry D Anderson; Tania Jain; Saad S Kenderian; Olalekan O Oluwole; Gunjan L Shah; Jakub Svoboda; Mehdi Hamadani
Journal:  Transplant Cell Ther       Date:  2022-06-26

Review 3.  CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure.

Authors:  Ana Carolina Caballero; Laura Escribà-Garcia; Carmen Alvarez-Fernández; Javier Briones
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

4.  Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy.

Authors:  Yuan-Yuan Hao; Pan-Pan Chen; Xiang-Gui Yuan; Ai-Qi Zhao; Yun Liang; Hui Liu; Wen-Bin Qian
Journal:  World J Clin Cases       Date:  2022-07-06       Impact factor: 1.534

5.  Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.

Authors:  Anqi Dai; Guido Ghilardi; Andrea Facciabene; Marcel R M van den Brink; Marco Ruella; Melody Smith; Kimberly V Amelsberg; Sean M Devlin; Raymone Pajarillo; John B Slingerland; Silvia Beghi; Pamela S Herrera; Paul Giardina; Annelie Clurman; Emmanuel Dwomoh; Gabriel Armijo; Antonio L C Gomes; Eric R Littmann; Jonas Schluter; Emily Fontana; Ying Taur; Jae H Park; Maria Lia Palomba; Elizabeth Halton; Josel Ruiz; Tania Jain; Martina Pennisi; Aishat Olaide Afuye; Miguel-Angel Perales; Craig W Freyer; Alfred Garfall; Shannon Gier; Sunita Nasta; Daniel Landsburg; James Gerson; Jakub Svoboda; Justin Cross; Elise A Chong; Sergio Giralt; Saar I Gill; Isabelle Riviere; David L Porter; Stephen J Schuster; Michel Sadelain; Noelle Frey; Renier J Brentjens; Carl H June; Eric G Pamer; Jonathan U Peled
Journal:  Nat Med       Date:  2022-03-14       Impact factor: 87.241

6.  Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.

Authors:  Audrey M Sigmund; Nathan Denlinger; Ying Huang; David Bond; Timothy Voorhees; Amneet Bajwa; Patrick Elder; Jonathan E Brammer; Ayman Saad; Sam Penza; Sumithira Vasu; Marcos de Lima; Samantha Jaglowski; Adam S Kittai
Journal:  Transplant Cell Ther       Date:  2022-03-04

Review 7.  Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.

Authors:  Nikeshan Jeyakumar; Melody Smith
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

Review 8.  How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure.

Authors:  Jennifer M Logue; Julio C Chavez
Journal:  Curr Treat Options Oncol       Date:  2021-10-26

9.  Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy.

Authors:  Ajlan Al Zaki; Lei Feng; Grace Watson; Sairah A Ahmed; Haleigh Mistry; Loretta J Nastoupil; Misha Hawkins; Ranjit Nair; Swaminathan P Iyer; Hun J Lee; Raphael E Steiner; Christopher R Flowers; Elizabeth J Shpall; Partow Kebriaei; Sattva S Neelapu; Jason R Westin; Paolo Strati
Journal:  Blood Adv       Date:  2022-05-10

10.  CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.

Authors:  Jay Y Spiegel; Shabnum Patel; Lori Muffly; Nasheed M Hossain; Jean Oak; John H Baird; Matthew J Frank; Parveen Shiraz; Bita Sahaf; Juliana Craig; Maria Iglesias; Sheren Younes; Yasodha Natkunam; Michael G Ozawa; Eric Yang; John Tamaresis; Harshini Chinnasamy; Zach Ehlinger; Warren Reynolds; Rachel Lynn; Maria Caterina Rotiroti; Nikolaos Gkitsas; Sally Arai; Laura Johnston; Robert Lowsky; Robbie G Majzner; Everett Meyer; Robert S Negrin; Andrew R Rezvani; Surbhi Sidana; Judith Shizuru; Wen-Kai Weng; Chelsea Mullins; Allison Jacob; Ilan Kirsch; Magali Bazzano; Jing Zhou; Sean Mackay; Scott J Bornheimer; Liora Schultz; Sneha Ramakrishna; Kara L Davis; Katherine A Kong; Nirali N Shah; Haiying Qin; Terry Fry; Steven Feldman; Crystal L Mackall; David B Miklos
Journal:  Nat Med       Date:  2021-07-26       Impact factor: 87.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.